Keyword: Cidara Therapeutics
The trial found the drug performed numerically better than Merck’s Cancidas, offering Cidara encouragement as it heads toward phase 3 data.
After hitting a roadblock early last year, Cidara is set to start phase 3 trials of its IV antifungal, rezafungin.
New York venture firm Aisling Capital has raised a solid chunk of cash for clinical-stage biotechs as it looks to build on some of its recent successes.
Struggling Teva bid farewell to longtime CFO Eyal Desheh, Immune Pharma's CEO Teper departed and Rgenix tapped ex-Novartis oncology scientist as CMO.
Cidara Therapeutics will stop work on its antifungal CD101 in women with acute VVC, after the topical candidate failed a mid-stage trial.